20mg semaglutide Semaglutide Research Peptide | GLP1-S

Trial design: 751 adults with obesity (BMI 30, or 27 with at least one comorbidity) No type 2 diabetes 72-week follow-up Tirzepatide 10mg or 15mg vs Semaglutide 2.4mg Results at 72 weeks: When looking at tirzepatide weight loss results from SURMOUNT-5 alongside semaglutide weight loss results from the STEP trials, the gap is consistent and statistically significant across every subgroup sex, age, baseline BMI, and presence of metabolic comorbidities

But the latest side effect is one we didnt see coming

Safety of Glutathione Via IV The safety and acceptance of Glutathione administered via intravenous (IV) infusion vary among individuals and regions

One notable difference is that tirzepatide is a dual-agonist (GLP-1 and GIP) while retatrutide is a triple-agonist (GLP-1, GIP, and glucagon)